8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 26, 2026·SEC
Ernexa Therapeutics Inc.(ERNA)Earnings, Financials & Key Ratios
ERNA•NASDAQ
$7.82
$2M mkt cap·Price updated May 7, 2026
AboutErnexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$9M+35.5%
- Net Income-$14M+68.3%
- EPS (Diluted)-56.00-42.7%
- ROE-687.47%+69.6%
- ROIC-840.56%-1228.4%
- Debt/Equity0.20-49.2%
- Interest Coverage-345.15-6072.2%
ERNA Key Insights
Ernexa Therapeutics Inc. (ERNA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 77.8% through buybacks
- ✓Trading at only 0.8x book value
✗Weaknesses
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ERNA Price & Volume
Ernexa Therapeutics Inc. (ERNA) stock price & volume — 10-year historical chart
Loading chart...
ERNA Growth Metrics
Ernexa Therapeutics Inc. (ERNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM68.38%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM85.51%
Return on Capital
10 Years-139.43%
5 Years-254.72%
3 Years-170.89%
Last Year-368.92%
ERNA Peer Comparison
Ernexa Therapeutics Inc. (ERNA) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 280.32M | 2.43 | -2.11 | -51.24% | -20.51% | -65.79% | 0.38 | |
 CRSP | 5.06B | 52.42 | -8.10 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.23B | 31.47 | -38.85 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.62B | 13.71 | -3.60 | 16.92% | -6.1% | -56.63% | 0.14 | |
 EDIT | 296.54M | 3.03 | -1.68 | -100% | -5.23% | 0.66 | ||
 KYMR | 6.91B | 84.63 | -22.94 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ALNY | 39.48B | 295.91 | 127 | 65.19% | 13.46% | 98.29% | 1.62 | |
 SGMO | 21.54M | 0.10 | -0.21 | -67.2% | -331.28% | -8.14% | 1.34 |
Compare ERNA vs Peers
Ernexa Therapeutics Inc. (ERNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ERNA Income Statement
Ernexa Therapeutics Inc. (ERNA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 21.27M | 23.34M | 19.81M | 0 | 0 | 0 | 68K | 582K | 0 |
| Revenue Growth % | -4.65% | 9.69% | -15.12% | -100% | - | - | - | 755.88% | -100% |
| Cost of Goods Sold | 7.09M | 8.38M | 7.84M | 98K | 0 | 0 | 236K | 96K | 263K |
| COGS % of Revenue | 33.32% | 35.93% | 39.6% | - | - | - | 347.06% | 16.49% | - |
| Gross Profit | 14.19M▲ 0% | 14.95M▲ 5.4% | 11.96M▼ 20.0% | -98K▼ 100.8% | 0▲ 100.0% | 0▲ 0% | -168K▲ 0% | 486K▲ 389.3% | -263K▼ 154.1% |
| Gross Margin % | 66.68% | 64.07% | 60.4% | - | - | - | -247.06% | 83.51% | - |
| Gross Profit Growth % | 0.04% | 5.39% | -19.98% | -100.82% | 100% | - | - | 389.29% | -154.12% |
| Operating Expenses | 15.59M | 14.49M | 13.18M | 7.15M | 113.73M | 33.22M | 20.97M | 16.16M | 9.06M |
| OpEx % of Revenue | 73.27% | 62.08% | 66.52% | - | - | - | 30833.82% | 2776.63% | - |
| Selling, General & Admin | 15.45M | 14.41M | 13.15M | 3.3M | 14.72M | 16.55M | 14.59M | 13.13M | 5.16M |
| SG&A % of Revenue | 72.61% | 61.77% | 66.39% | - | - | - | 21450% | 2256.36% | - |
| Research & Development | 139K | 72K | 26K | 3.95M | 12.71M | 10.39M | 5.92M | 4.6M | 4.16M |
| R&D % of Revenue | 0.65% | 0.31% | 0.13% | - | - | - | 8705.88% | 791.07% | - |
| Other Operating Expenses | 0 | 0 | 0 | -98K | 86.3M | 6.27M | 461K | -1.58M | -263K |
| Operating Income | -1.4M▲ 0% | 464K▲ 133.1% | -1.21M▼ 361.2% | -7.25M▼ 498.0% | -113.73M▼ 1469.2% | -33.22M▲ 70.8% | -21.14M▲ 36.4% | -15.67M▲ 25.8% | -9.32M▲ 40.5% |
| Operating Margin % | -6.59% | 1.99% | -6.12% | - | - | - | -31080.88% | -2693.13% | - |
| Operating Income Growth % | 38.45% | 133.1% | -361.21% | -498.02% | -1469.15% | 70.79% | 36.37% | 25.84% | 40.54% |
| EBITDA | 915K | 3.23M | 1.96M | -7.15M | -113.27M | -32.72M | -20.01M | -14.04M | -9.06M |
| EBITDA Margin % | 4.3% | 13.83% | 9.88% | - | - | - | -29429.41% | -2411.68% | - |
| EBITDA Growth % | 50.25% | 252.79% | -39.41% | -465.54% | -1484.24% | 71.11% | 38.84% | 29.86% | 35.48% |
| D&A (Non-Cash Add-back) | 2.32M | 2.76M | 3.17M | 98K | 459K | 497K | 1.12M | 1.64M | 263K |
| EBIT | -513K | 66K | -1.77M | -26.49M | -122.41M | -24.5M | -21.06M | -37.76M | -9.32M |
| Net Interest Income | 0 | 0 | -249K | -43K | -74K | -30K | -476K | -6.5M | 56K |
| Interest Income | 0 | 0 | - | 0 | 0 | 0 | 138K | 249K | 83K |
| Interest Expense | 498K | 389K | 249K | 43K | 74K | 30K | 614K | 6.75M | 27K |
| Other Income/Expense | 391K | -787K | -808K | -19.28M | -8.75M | 8.68M | -536K | -28.84M | -4.81M |
| Pretax Income | -1.01M▲ 0% | -323K▲ 68.1% | -2.02M▼ 525.4% | -26.53M▼ 1213.4% | -122.48M▼ 361.7% | -24.53M▲ 80.0% | -21.67M▲ 11.7% | -44.51M▼ 105.4% | -14.13M▲ 68.3% |
| Pretax Margin % | -4.75% | -1.38% | -10.2% | - | - | - | -31869.12% | -7647.59% | - |
| Income Tax | 66K | -64K | 27K | 0 | 64K | 45K | -3K | 30K | -45K |
| Effective Tax Rate % | -6.53% | 19.81% | -1.34% | 0% | -0.05% | -0.18% | 0.01% | -0.07% | 0.32% |
| Net Income | -1.08M▲ 0% | -259K▲ 76.0% | -2.05M▼ 690.3% | 11.91M▲ 681.6% | -122.55M▼ 1129.3% | -24.58M▲ 79.9% | -21.67M▲ 11.8% | -44.54M▼ 105.6% | -14.1M▲ 68.3% |
| Net Margin % | -5.06% | -1.11% | -10.34% | - | - | - | -31864.71% | -7652.75% | - |
| Net Income Growth % | 63.15% | 75.95% | -690.35% | 681.63% | -1129.27% | 79.94% | 11.84% | -105.55% | 68.34% |
| Net Income (Continuing) | -1.08M | -259K | -2.05M | -26.53M | -122.55M | -24.58M | -21.67M | -44.54M | -14.1M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -441.00▲ 0% | -96.25▲ 78.2% | -712.00▼ 639.7% | -87.75▲ 87.7% | -1415.25▼ 1512.8% | -201.50▲ 85.8% | -102.00▲ 49.4% | -39.25▲ 61.5% | -56.00▼ 42.7% |
| EPS Growth % | 71.29% | 78.17% | -639.74% | 87.68% | -1512.82% | 85.76% | 49.38% | 61.52% | -42.68% |
| EPS (Basic) | -441.00 | -96.25 | -712.00 | -87.75 | -1415.25 | -201.50 | -102.00 | -39.25 | -56.00 |
| Diluted Shares Outstanding | 2.44K | 2.69K | 2.88K | 69.31K | 86.6K | 122.04K | 212.56K | 1.14M | 252.28K |
| Basic Shares Outstanding | 2.44K | 2.69K | 2.88K | 69.31K | 86.6K | 122.04K | 212.56K | 1.14M | 252.28K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ERNA Balance Sheet
Ernexa Therapeutics Inc. (ERNA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.64M | 6.79M | 6.07M | 1.73M | 18.77M | 13.68M | 9.6M | 2.35M | 3.13M |
| Cash & Short-Term Investments | 3.38M | 2.59M | 3.26M | 1.63M | 16.98M | 11.45M | 7.58M | 1.73M | 1.88M |
| Cash Only | 3.38M | 2.59M | 3.26M | 1.63M | 16.98M | 11.45M | 7.58M | 1.73M | 1.88M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 714K | 1.14M | 1.2M | 0 | 684K | 951K | 425K | 437K | 95K |
| Days Sales Outstanding | 12.25 | 17.88 | 22.02 | - | - | - | 2.28K | 274.06 | - |
| Inventory | 4.87M | 2.54M | 1.09M | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 250.54 | 110.52 | 50.73 | - | - | - | - | - | - |
| Other Current Assets | 680K | 517K | 526K | 0 | 0 | 0 | 1.6M | 186K | 1.15M |
| Total Non-Current Assets | 6.93M | 8.08M | 9.21M | 11.17M | 12.76M | 8.6M | 39.53M | 2.92M | 2.7M |
| Property, Plant & Equipment | 3.68M | 4.67M | 4.92M | 2.69M | 3.24M | 1.27M | 33.27M | 755K | 547K |
| Fixed Asset Turnover | 5.78x | 5.00x | 4.02x | - | - | - | 0.00x | 0.77x | - |
| Goodwill | 1M | 667K | 696K | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M | 2.04M |
| Intangible Assets | 0 | 0 | 1.92M | 5.99M | 5.99M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.09M | 200K | 150K | -449K | 1M | 59K | 0 | 0 | 0 |
| Other Non-Current Assets | 791K | 527K | 371K | 453K | 488K | 5.23M | 4.21M | 118K | 110K |
| Total Assets | 16.57M▲ 0% | 14.86M▼ 10.3% | 15.28M▲ 2.8% | 12.91M▼ 15.5% | 31.52M▲ 144.3% | 22.28M▼ 29.3% | 49.13M▲ 120.5% | 5.27M▼ 89.3% | 5.83M▲ 10.7% |
| Asset Turnover | 1.28x | 1.57x | 1.30x | - | - | - | 0.00x | 0.11x | - |
| Asset Growth % | -3.3% | -10.3% | 2.77% | -15.51% | 144.27% | -29.33% | 120.53% | -89.28% | 10.72% |
| Total Current Liabilities | 10.75M | 4.02M | 6.09M | 3.13M | 3.68M | 7.65M | 6.57M | 2.94M | 3.11M |
| Accounts Payable | 390K | 271K | 835K | 1.27M | 1.75M | 1.62M | 1.07M | 1.72M | 1.13M |
| Days Payables Outstanding | 20.08 | 11.8 | 38.86 | 4.75K | - | - | 1.65K | 6.54K | 1.56K |
| Short-Term Debt | 5.24M | 1.04M | 3.17M | 526K | 0 | 1.75M | 0 | 207K | 213K |
| Deferred Revenue (Current) | 3.56M | 1.37M | 460K | 76K | 0 | 0 | 190K | 0 | 0 |
| Other Current Liabilities | 1.56M | 1.34M | 1.04M | 681K | 903K | -322K | 109K | 12K | 1.77M |
| Current Ratio | 0.90x | 1.69x | 1.00x | 0.55x | 5.10x | 1.79x | 1.46x | 0.80x | 1.01x |
| Quick Ratio | 0.44x | 1.06x | 0.82x | 0.55x | 5.10x | 1.79x | 1.46x | 0.80x | 1.01x |
| Cash Conversion Cycle | 242.71 | 116.6 | 33.89 | - | - | - | - | - | - |
| Total Non-Current Liabilities | 287K | 3.92M | 4.09M | 2.12M | 2.34M | 2.52M | 40.33M | 630K | 320K |
| Long-Term Debt | 8K | 2.73M | 0 | 194K | 0 | 1.21M | 6.77M | 0 | 0 |
| Capital Lease Obligations | 0 | 41K | 2.91M | 1.91M | 2.3M | 887K | 32.85M | 477K | 277K |
| Deferred Tax Liabilities | 424K | 41K | 1.13M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | -208K | 1.08M | 44K | 23K | 47K | 425K | 307K | 153K | 43K |
| Total Liabilities | 11.03M | 7.95M | 10.19M | 5.25M | 6.02M | 10.17M | 46.9M | 3.57M | 3.43M |
| Total Debt | 5.41M | 3.81M | 6.08M | 2.9M | 2.72M | 4.14M | 41.84M | 684K | 490K |
| Net Debt | 2.03M | 1.23M | 2.82M | 1.27M | -14.26M | -7.31M | 34.27M | -1.04M | -1.39M |
| Debt / Equity | 0.98x | 0.55x | 1.19x | 0.38x | 0.11x | 0.34x | 18.74x | 0.40x | 0.20x |
| Debt / EBITDA | 5.91x | 1.18x | 3.11x | - | - | - | - | - | - |
| Net Debt / EBITDA | 2.22x | 0.38x | 1.44x | - | - | - | - | - | - |
| Interest Coverage | -1.03x | 0.17x | -7.11x | -616.00x | -1654.15x | -816.80x | -34.29x | -5.59x | -345.15x |
| Total Equity | 5.54M▲ 0% | 6.92M▲ 24.9% | 5.09M▼ 26.4% | 7.66M▲ 50.4% | 25.5M▲ 233.0% | 12.11M▼ 52.5% | 2.23M▼ 81.6% | 1.7M▼ 23.8% | 2.4M▲ 41.2% |
| Equity Growth % | 36.09% | 24.95% | -26.4% | 50.44% | 232.99% | -52.53% | -81.56% | -23.82% | 41.15% |
| Book Value per Share | 2266.99 | 2573.29 | 1770.78 | 110.50 | 294.50 | 99.21 | 10.51 | 1.50 | 9.52 |
| Total Shareholders' Equity | 5.54M | 6.92M | 5.09M | 7.66M | 25.5M | 12.11M | 2.23M | 1.7M | 2.4M |
| Common Stock | 13K | 14K | 14K | 25.8M | 13K | 26K | 27K | 257K | 39K |
| Retained Earnings | -129.12M | -129.39M | -131.46M | -18.14M | -140.7M | -165.3M | -186.98M | -231.54M | -245.64M |
| Treasury Stock | -456K | -456K | -456K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 345K | 200K | 268K | 245K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ERNA Cash Flow Statement
Ernexa Therapeutics Inc. (ERNA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 549K | 1.36M | 2.74M | -8.1M | -23.49M | -20.98M | -20.41M | -15.84M | -7.02M |
| Operating CF Margin % | 2.58% | 5.85% | 13.85% | - | - | - | -30011.76% | -2720.96% | - |
| Operating CF Growth % | 2286.96% | 148.63% | 101.03% | -395.23% | -189.94% | 10.69% | 2.71% | 22.4% | 55.69% |
| Net Income | -1.08M | -259K | -2.05M | -26.53M | -122.55M | -24.58M | -21.67M | -44.54M | -14.08M |
| Depreciation & Amortization | 2.32M | 2.76M | 3.17M | 98K | 459K | 497K | 1.12M | 1.64M | 263K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 5.24M | 2.94M | 1.24M | 1.52M | 1.5M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 10.05M | 6.92M | 1.66M | 19.33M | 95.65M | -3.54M | 1.01M | 27.52M | 5.36M |
| Working Capital Changes | -1.73M | -2.27M | -37K | -999K | -2.29M | 3.71M | -2.12M | -1.98M | -51K |
| Change in Receivables | 142K | -507K | -248K | 0 | -659K | -262K | 527K | -12K | -408K |
| Change in Inventory | -3.93M | 431K | 337K | 52K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -586K | -186K | 669K | -1.73M | -485K | 2.03M | -2.9M | 183K | 60K |
| Cash from Investing | -1.45M | -1.58M | -1.06M | -39K | -22.74M | -47K | -19K | -365K | -37K |
| Capital Expenditures | -1.45M | -1.61M | -1.09M | -39K | -154K | -297K | -19K | -369K | -37K |
| CapEx % of Revenue | 6.83% | 6.91% | 5.52% | - | - | - | 27.94% | 63.4% | - |
| Acquisitions | 0 | 33K | 29K | 0 | -22.71M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 119K | 250K | 0 | 4K | 0 |
| Cash from Financing | -1.47M | -303K | -1.1M | 4.67M | 61.59M | 19.58M | 16.56M | 6.26M | 7.21M |
| Debt Issued (Net) | -3.23M | -1.65M | 0 | 310K | -942K | -2K | 16.5M | 5.29M | 2.25M |
| Equity Issued (Net) | 1.77M | 1.38M | 0 | 4.36M | 62.52M | 19.71M | 320K | 1.14M | 4.96M |
| Dividends Paid | -16K | -16K | -16K | 0 | -8K | -16K | -16K | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -17K | -1.08M | 0 | 10K | -109K | -251K | -169K | 0 |
| Net Change in Cash | -2.31M▲ 0% | -792K▲ 65.7% | 673K▲ 185.0% | -1.63M▼ 342.1% | 15.36M▲ 1042.6% | -1.44M▼ 109.4% | -3.87M▼ 168.1% | -9.94M▼ 156.8% | 155K▲ 101.6% |
| Free Cash Flow | -903K▲ 0% | -247K▲ 72.6% | 1.65M▲ 768.0% | -8.14M▼ 593.3% | -23.64M▼ 190.4% | -21.27M▲ 10.0% | -20.43M▲ 4.0% | -16.2M▲ 20.7% | -7.05M▲ 56.5% |
| FCF Margin % | -4.24% | -1.06% | 8.33% | - | - | - | -30039.71% | -2784.36% | - |
| FCF Growth % | -10.53% | 72.65% | 768.02% | -593.33% | -190.44% | 10.02% | 3.98% | 20.67% | 56.47% |
| FCF per Share | -369.78 | -91.89 | 573.91 | -117.44 | -273.00 | -174.31 | -96.10 | -14.27 | -27.96 |
| FCF Conversion (FCF/Net Income) | -0.51x | -5.27x | -1.34x | -0.68x | 0.19x | 0.85x | 0.94x | 0.36x | 0.50x |
| Interest Paid | 0 | 0 | 0 | 0 | 225K | 30K | 20K | 48K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 1K | 15K | 4K | 2K | 0 |
ERNA Key Ratios
Ernexa Therapeutics Inc. (ERNA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -73.85% | -22.43% | -4.16% | -34.09% | 186.76% | -739.05% | -130.7% | -302.2% | -2264.31% | -687.47% |
| Return on Invested Capital (ROIC) | -22.5% | -14.53% | 4.43% | -11.32% | -64.56% | -845.84% | -310.61% | -76.76% | -63.27% | -840.56% |
| Gross Margin | 63.55% | 66.68% | 64.07% | 60.4% | - | - | - | -247.06% | 83.51% | - |
| Net Margin | -13.1% | -5.06% | -1.11% | -10.34% | - | - | - | -31864.71% | -7652.75% | - |
| Debt / Equity | 2.10x | 0.98x | 0.55x | 1.19x | 0.38x | 0.11x | 0.34x | 18.74x | 0.40x | 0.20x |
| Interest Coverage | -4.01x | -1.03x | 0.17x | -7.11x | -616.00x | -1654.15x | -816.80x | -34.29x | -5.59x | -345.15x |
| FCF Conversion | -0.01x | -0.51x | -5.27x | -1.34x | -0.68x | 0.19x | 0.85x | 0.94x | 0.36x | 0.50x |
| Revenue Growth | -9% | -4.65% | 9.69% | -15.12% | -100% | - | - | - | 755.88% | -100% |
ERNA SEC Filings & Documents
Ernexa Therapeutics Inc. (ERNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ERNA Frequently Asked Questions
Ernexa Therapeutics Inc. (ERNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ernexa Therapeutics Inc. (ERNA) saw revenue decline by 100.0% over the past year.
Ernexa Therapeutics Inc. (ERNA) reported a net loss of $14.1M for fiscal year 2025.
Dividend & Returns
Ernexa Therapeutics Inc. (ERNA) has a return on equity (ROE) of -687.5%. Negative ROE indicates the company is unprofitable.
Ernexa Therapeutics Inc. (ERNA) had negative free cash flow of $7.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More ERNA
Ernexa Therapeutics Inc. (ERNA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates